Quest Partners LLC Buys 4,223 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Quest Partners LLC boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 31.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,858 shares of the company’s stock after buying an additional 4,223 shares during the quarter. Quest Partners LLC’s holdings in Syndax Pharmaceuticals were worth $344,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in SNDX. Northwestern Mutual Wealth Management Co. bought a new position in Syndax Pharmaceuticals during the second quarter worth about $27,000. Values First Advisors Inc. bought a new position in Syndax Pharmaceuticals during the third quarter worth about $30,000. nVerses Capital LLC bought a new position in Syndax Pharmaceuticals during the second quarter worth about $33,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the period. Finally, Quarry LP lifted its holdings in shares of Syndax Pharmaceuticals by 75.0% in the second quarter. Quarry LP now owns 6,125 shares of the company’s stock worth $126,000 after buying an additional 2,625 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus increased their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Citigroup increased their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. StockNews.com downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Bank of America increased their price target on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. Finally, HC Wainwright raised their target price on shares of Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a “buy” rating in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $37.64.

Syndax Pharmaceuticals Stock Up 4.0 %

NASDAQ:SNDX opened at $16.73 on Tuesday. The stock has a market cap of $1.43 billion, a P/E ratio of -4.77 and a beta of 0.92. The firm’s fifty day simple moving average is $18.60 and its 200 day simple moving average is $19.97. Syndax Pharmaceuticals, Inc. has a twelve month low of $15.00 and a twelve month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter last year, the firm earned ($0.73) EPS. On average, analysts expect that Syndax Pharmaceuticals, Inc. will post -3.69 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).